# Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

> **NCT03595592** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Fondazione Michelangelo** · enrollment: 650 (estimated)

## Conditions studied

- Invasive Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Atezolizumab
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT03595592
- **Lead sponsor:** Fondazione Michelangelo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-07
- **Primary completion:** 2026-12-15
- **Final completion:** 2027-03-15
- **Target enrollment:** 650 (ESTIMATED)
- **Last updated:** 2024-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03595592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03595592, "Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03595592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*